Aod 9604 Peptide​ | Aod 9604 5mg​ | Reconstitute Aod 9604 5mg​ 

Aod 9604 Peptide​, Aod 9604 5mg​, Reconstitute Aod 9604 5mg​. AOD‑9604 peptide is a synthetic fragment of human growth hormone (HGH). Specifically, it is derived from amino acids 177–191 of the HGH molecule, with an added tyrosine at the end to improve stability. Its name stands for “Anti‑Obesity Drug 9604.”

Unlike full HGH, which influences growth, muscle development, and insulin‑like growth factor (IGF‑1), AOD‑9604 was designed to isolate the fat‑burning properties of HGH without the anabolic or diabetogenic side effects.

It is classified as a research peptide and has been studied for:

• Fat metabolism
• Obesity treatment
• Cartilage and joint repair

Characteristics of AOD‑9604 Peptide | Aod 9604 Peptide​

AOD‑9604 characteristics make it distinct from other peptides:

• Synthetic peptide fragment (16 amino acids long).
• Non‑anabolic: does not increase muscle mass.
• Lipolytic: stimulates fat breakdown.
• No effect on blood sugar or IGF‑1.
• Stable in lyophilized powder form.
• Administered subcutaneously (injection under the skin).
• Vial sizes: commonly 2 mg, 5 mg, or 10 mg.

Mechanism of Action | Reconstitute Aod 9604 5mg​ | Aod 9604 Peptide​

The mechanism of AOD‑9604 is tied to its ability to mimic HGH’s lipolytic region:

1. Stimulates lipolysis — the breakdown of stored fat into free fatty acids.
2. Inhibits lipogenesis — prevents the formation of new fat deposits.
3. Targets adipose tissue directly — especially stubborn fat areas.
4. Does not affect appetite — unlike GLP‑1 agonists.
5. Does not raise IGF‑1 — avoiding risks of insulin resistance.

This makes AOD‑9604 a fat‑specific peptide rather than a growth‑ or appetite‑modulating compound.

Effects of AOD‑9604 | Aod 9604 5mg

The effects observed in research include:

• Fat reduction: particularly visceral and abdominal fat.
• Improved lipid metabolism.
• Cartilage repair potential: animal studies suggest regenerative effects.
• Joint health support: possible benefits for osteoarthritis.
• Minimal endocrine disruption compared to HGH.

Unlike anabolic peptides, AOD‑9604 does not increase muscle mass or strength directly.

AOD‑9604 5 mg

AOD‑9604 5 mg refers to the standard vial size used in research.

• Each vial contains 5 milligrams of lyophilized peptide powder.
• Must be reconstituted with bacteriostatic water before use.
• Provides flexibility in dosing (e.g., 300–500 mcg daily).

Reconstitute AOD‑9604 5 mg

Reconstitution is the process of preparing the peptide for injection.

Steps:

1. Clean vial stopper with alcohol.
2. Draw bacteriostatic water (1–2 mL).
3. Inject slowly down the side of the vial.
4. Swirl gently until dissolved (do not shake).
5. Store in refrigerator (2–8 °C).

Concentration Examples

• 5 mg + 1 mL → 5000 mcg/mL
• 5 mg + 2 mL → 2500 mcg/mL

This allows precise measurement of microgram doses.

AOD‑9604 Dosage | Aod 9604 Peptide​

AOD‑9604 dosage varies depending on research protocols.

1. Standard Range

• 300 mcg/day subcutaneous injection.
• Often taken in the morning, fasted.

2. Enhanced Range

• 500 mcg/day for stronger lipolytic effect.

3. Clinical Trial Maximum

• Up to 1000 mcg/day tested in obesity studies.

4. Cycle Length

• 8–12 weeks typical research cycle.
• Some extended to 20 weeks.

5. Injection Site

• Abdomen or areas with higher fat deposits.

6. Timing

• Fasted state is critical; insulin blunts lipolysis.

Benefits of AOD‑9604 | Aod 9604 Peptide​

AOD‑9604 benefits include:

1. Targeted fat loss without muscle gain.
2. No IGF‑1 spike → lower risk of insulin resistance.
3. Cartilage/joint repair potential (animal data).
4. Synergy with other peptides (MOTS‑c, Tesamorelin).
5. Minimal side effects compared to HGH.

Comparison With Other Compounds | Aod 9604 Peptide​

• Not FDA‑approved for therapeutic use.
• On WADA prohibited list (banned in sports).
• Side effects: mild injection‑site irritation, occasional nausea.
• Long‑term human safety data limited.

Final Thoughts | Aod 9604 Peptide​ | abolish

AOD‑9604 is a research peptide fragment of HGH designed to promote fat metabolism without anabolic or diabetogenic effects.

• Definition: Synthetic HGH fragment (177–191).
• Characteristics: Lipolytic, non‑anabolic, subcutaneous injection.
• Effects: Fat breakdown, possible joint repair.
• 5 mg vials: Standard research format.
• Reconstitution: With bacteriostatic water, 1–2 mL.
• Dosage: 300–500 mcg/day typical; up to 1000 mcg/day in trials.
• Benefits: Fat loss, joint support, minimal side effects.
• Comparison: Distinct from GLP‑1 agonists and anabolic peptides.